Evidence map›Paper›PMID 27364697›Full record

ArticleNeurotoxicity research2016

Interference of α-Synuclein Uptake by Monomeric β-Amyloid1-40 and Potential Core Acting Site of the Interference.

Daniel K Y Chan, Nady Braidy, Ying Hua Xu, Tim Chataway, Feng Guo, Gilles J Guillemin, Charlie Teo, Wei Ping Gai

Abstract read
PubMed Publisher
In one paragraph

Article in Neurotoxicity research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.4field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Daniel K Y ChanFaculty of Medicine, University of New South Wales, Sydney, 2052, Australia. d.chan@unsw.edu.au.
Nady BraidyFaculty of Medicine, University of New South Wales, Sydney, 2052, Australia.
Ying Hua XuFaculty of Medicine, University of New South Wales, Sydney, 2052, Australia.
Tim ChatawayDepartment of Human Physiology and the Centre for Neuroscience, School of Medicine, Flinders University, Bedford Park, SA, 5042, Australia.
Feng GuoDepartment of Human Physiology and the Centre for Neuroscience, School of Medicine, Flinders University, Bedford Park, SA, 5042, Australia.
Gilles J GuilleminFaculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, 2109, Australia.
Charlie TeoFaculty of Medicine, University of New South Wales, Sydney, 2052, Australia.
Wei Ping GaiDepartment of Surgery and Centre for Neuroscience, School of Medicine, Flinders University, Bedford Park, SA, 5042, Australia.
Flinders University · AUBankstown Lidcombe Hospital · AUIngham Institute · AUMacquarie University · AUNeuroscience Research Australia · AUUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Increasing evidence suggests an important role of alpha-synuclein (α-Syn) in the pathogenesis of Parkinson's disease (PD). The inter-neuronal spread of α-Syn via exocytosis and endocytosis has been proposed as an explanation for the neuropathological findings of PD in sub-clinical and clinical phases. Therefore, interfering the uptake of α-Syn by neurons may be an important step in slowing or modifying the propagation of the disease. The purposes of our study were to investigate if the uptake of α-Syn fibrils can be specifically interfered with monomeric β-Amyloid1-40 (Aβ40) and to characterise the core acting site of interference. Using a radioisotope-labelled uptake assay, we found an 80 % uptake reduction of α-Syn fibrils in neurons interfered with monomeric Aβ40, but not β-Amyloid1-42 (Aβ42) as compared to controls. This finding was further confirmed by enzyme-linked immunosorbent assay (ELISA) with α-Syn uptake reduced from about 80 % (Aβ42) to about 20 % (Aβ40) relative to controls. To define the region of Aβ40 peptide capable of the interference, we explored shorter peptides with less amino acid residues from both the C-terminus and N-terminus. We found that the interference effect was preserved if amino acid residue was trimmed to position 11 (from N-terminus) and 36 (from C-terminus), but dropped off significantly if residues were trimmed beyond these positions. We therefore deduced that the "core acting site" lies between amino acid residue positions 12-36. These findings suggest α-Syn uptake can be interfered with monomeric Aβ40 and that the core acting site of interference might lie between amino acid residue positions 12-36.

Indexed as

alpha-SynucleinAmino Acid SequenceAmyloid beta-PeptidesBrainCells, CulturedEndocytosisEnzyme-Linked Immunosorbent AssayEscherichia coliHumansHydrazonesImmunochemistryMicroscopy, FluorescenceNeuronsPeptide FragmentsRecombinant ProteinsSertralinealpha-SynucleinAmyloid beta-Peptidesamyloid beta-protein (1-40)amyloid beta-protein (1-42)HydrazonesMAPT protein, humanN'-(3,4-dihydroxybenzylidene)-3-hydroxy-2-naphthahydrazidePeptide FragmentsRecombinant ProteinsSertralineSNCA protein, humantau ProteinsInterferenceα-synucleinα-synuclein uptakeβ-amyloid1–40β-amyloid1–42

Identifiers

PMID27364697
OpenAlexW2469025994

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.